DaVita

NYSE: DVA

Stock price

235.58 USD

(+Infinity%) NaN day

By default your notes are visible only to you.

101.0

52-week range

239.6

235.58

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

8.3 %

Dividend Yield TTM

-

Market cap $

$ 15,121

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

23.7

Price / Book TTM

(21)

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

(2.1)

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

65.3 %

94 %

202.1 %

Free cash flow per share growth

(11.5) %

39.8 %

278.8 %

Earnings per share growth

(11.4) %

48.8 %

660.8 %

Founded: 1,979

Employees: 76,000

Business Summary:DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Fair Value Reference Estimate

Latest Earnings Call Takeaways

Annual Reports, Presentations And IR Contacts

Go to the website

DaVita — Financial Overview, Stock Price, Market Cap

DaVita is a company. Founded in 1979. As of July 14, 2026, the company's market capitalization is $15120702300 with a current stock price of $235.58.